A Pilot Study on the Effect of Vitamin D Treatment in Patients With Statin-Associated Myalgia
This study has been terminated.
(PI resigned.)
Sponsor:
Avera McKennan Hospital & University Health Center
Information provided by:
Avera McKennan Hospital & University Health Center
ClinicalTrials.gov Identifier:
NCT01274104
First received: January 6, 2011
Last updated: July 6, 2011
Last verified: July 2011
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Detailed Description:
The purpose of this study is to measure the effect vitamin D has in alleviating muscle pain or aches that may be caused by taking certain medications for treating high cholesterol.
Condition | Intervention | Phase |
---|---|---|
Hyperlipidemia |
Dietary Supplement: Vitamin D3 Other: Placebo |
Phase 1 |
Study Type: | Interventional |
Study Design: | Allocation: Randomized Endpoint Classification: Efficacy Study Intervention Model: Parallel Assignment Masking: Double Blind (Subject, Caregiver, Investigator) Primary Purpose: Supportive Care |
Official Title: | A Pilot Study on the Effect of Vitamin D Treatment in Patients With Statin-Associated Myalgia |
Resource links provided by NLM:
Further study details as provided by Avera McKennan Hospital & University Health Center:
Primary Outcome Measures:
- Brief Pain Inventory value [ Time Frame: 14 days ] [ Designated as safety issue: No ]Decrease in the level of muscle pain, based on values of Brief Pain Inventory short forms completed at the initial clinic visit and approximately four weeks later at the final clinic visit
Enrollment: | 0 |
Study Start Date: | October 2010 |
Study Completion Date: | July 2011 |
Primary Completion Date: | July 2011 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
Active Comparator: Vitamin D
Subjects will take 5,000 IU-capsules of vitamin D3 three times a day (for a total of 15,000 IU) for 14 days
|
Dietary Supplement: Vitamin D3
15,000 IU of Vitamin D3 every day for 14 days
Other Name: Cholecalciferol
|
Placebo Comparator: Control
Subjects will take 3 capsules of placebo every day for 14 days
|
Other: Placebo
Placebo
Other Name: Placebo
|
Detailed Description:
Participation in this study will consist of at least two study visits, expected to occur over a period of up to four weeks. Study-related medication will be provided at no cost to participants. Participants will receive either Vitamin D or placebo (sugar pill).
Eligibility
Ages Eligible for Study: | 18 Years to 88 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Men and women who are between the ages of 18 and 88 years old
- A muscle symptom defined as any of the following: Myalgia (muscle aches with normal CK); Myopathy (muscle aches with increased CK up to 5 times above the upper limit of normal); or Myopathy for the purpose of further evaluation (muscle aches with increased CK up to 5 times the upper limit of normal)
Exclusion Criteria:
- Women who are pregnant, breastfeeding or planning to become pregnant
- Morbidly obese with a BMI >40 kg/m2
- Travel to southern states, areas near the Equator, etc., or use of artificial tanning beds, such that study participants have increased sunlight/UV rays exposure in the past 30 days or at any point during the trial
- Currently (within the last 2 weeks) using any of the following supplements: Vitamin D-3 (Cholecalciferol) of more than 400 IU orally daily, which would not exclude typical multi-vitamin use; Vitamin D-2 (Ergocalciferol); Calcitriol; or Coenzyme Q10
- Documented to be hyperglycemic or laboratory results show hyperglycemia prior to randomization
- Renal dysfunction defined as glomerular filtration rate less than 60 mL/min.
- Documented to have parathyroid abnormalities or parathyroid hormone laboratory results show the study participant is outside of the normal limits
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01274104
Locations
United States, South Dakota | |
Avera Research Institute | |
Sioux Falls, South Dakota, United States, 57105 |
Sponsors and Collaborators
Avera McKennan Hospital & University Health Center
Investigators
Principal Investigator: | Wael Eid, MD | Avera McKennan Hospital & University Health Center |
More Information
No publications provided
Keywords provided by Avera McKennan Hospital & University Health Center:
Additional relevant MeSH terms:
ClinicalTrials.gov processed this record on October 18, 2012
No publications provided
Responsible Party: | Wael Eid, MD, Avera McKennan Hospital & University Health Center |
ClinicalTrials.gov Identifier: | NCT01274104 History of Changes |
Other Study ID Numbers: | ARI-1350-Myalgia |
Study First Received: | January 6, 2011 |
Last Updated: | July 6, 2011 |
Health Authority: | United States: Institutional Review Board |
Keywords provided by Avera McKennan Hospital & University Health Center:
statin-related myalgia high cholesterol |
Additional relevant MeSH terms:
Hyperlipidemias Dyslipidemias Lipid Metabolism Disorders Metabolic Diseases Cholecalciferol Vitamin D Ergocalciferols |
Vitamins Micronutrients Growth Substances Physiological Effects of Drugs Pharmacologic Actions Bone Density Conservation Agents |
ClinicalTrials.gov processed this record on October 18, 2012